Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver Failure

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Institute of Liver and Biliary Sciences, India
Information provided by (Responsible Party):
Institute of Liver and Biliary Sciences, India Identifier:
First received: April 27, 2013
Last updated: November 19, 2014
Last verified: November 2014

After successful screening diagnosis of cirrhosis and/or acute or chronic liver failure will be made. These patients will undergo detail clinical, biochemical and microbiological examination at baseline. Clinical examination and Biochemical evaluation will be done daily and signs of infection will be noted. Patients will undergo microbiological screening for infection every 48 hours. Patients suspected or diagnosed to be suffering from infections will be treated as per ILBS (Institute of Liver and Biliary Sciences) antibiotic policy. Site and etiology (bacterial and/or fungal) of infections will be noted in all patients at admission in liver specialty ICU (Intensive Care Unit) and during the ICU (Intensive Care Unit) stay. All the patients will be followed until discharge or death in ICU (Intensive Care Unit).

Acute Liver Failure
Chronic Liver Failure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver Failure Admitted in Liver Specialty ICU (Intensive Care Unit)- An Observational Study

Resource links provided by NLM:

Further study details as provided by Institute of Liver and Biliary Sciences, India:

Primary Outcome Measures:
  • Mortality within 1 month during ICU (Intensive Care Unit) stay. [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number of days stayed in ICU (Intensive Care Unit). [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
  • Risk factors determination in development of multidrug resistance bacteria.Risk factors are defined as Nosocomial infection,HCA (Health Care Associated)infection,Recent Hospitalization. [ Time Frame: 30 days ] [ Designated as safety issue: No ]
  • Proportion of patients with organ failure in both groups. [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 300
Study Start Date: June 2013
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
subjects with infection at admission.
subjects without infection at admission.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Tertiary Care Center.


Inclusion Criteria:

  • A clinical, radiological or histological diagnosis of cirrhosis and/or ACLF (Acute on Chronic Liver Failure).
  • Age > 18years

Exclusion Criteria:

  • Previous liver transplantation.
  • Patients who died within 8 hours of ICU (Intensive Care Unit) admission.
  • Acute liver failure
  • Lack of consent
  • Patient on steroids/ or any other immunosuppressive medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01872767

Contact: Dr Ambrish Sahney, MD +91-11-01146300000
Contact: Dr Ankit Bhardwaj +91-011-46300000

Institute of Liver & Biliary Sciences. Recruiting
New Delhi, Delhi, India, 110070
Contact: Dr Amrish Sahney, MD    +91-011-46300000   
Principal Investigator: Dr Amrish Sahney, MD         
Sponsors and Collaborators
Institute of Liver and Biliary Sciences, India
Principal Investigator: Amrish Sahney, MD Institute of Liver & Biliary Sciences.
  More Information

No publications provided

Responsible Party: Institute of Liver and Biliary Sciences, India Identifier: NCT01872767     History of Changes
Other Study ID Numbers: ACLF-ILBS-0003
Study First Received: April 27, 2013
Last Updated: November 19, 2014
Health Authority: India: Institutional Review Board

Keywords provided by Institute of Liver and Biliary Sciences, India:
Acute on Chronic Liver Failure (ACLF),Cirrhosis,
Institute of Liver & Biliary Sciences (ILBS)

Additional relevant MeSH terms:
End Stage Liver Disease
Liver Cirrhosis
Liver Failure
Digestive System Diseases
Hepatic Insufficiency
Liver Diseases processed this record on February 27, 2015